Keio University

Regarding the Manufacturing and Marketing Approval of Hemsite®, Japan's First Gene Panel Test for Hematologic Malignancies

Publish: September 24, 2024
Public Relations Office

September 24, 2024

Otsuka Pharmaceutical Co., Ltd.

National Cancer Center Japan

Kyushu University

Kyoto University

Nagoya Medical Center, National Hospital Organization

The Institute of Medical Science, The University of Tokyo

Keio University School of Medicine

We are pleased to announce that Otsuka Pharmaceutical Co., Ltd. (Head Office: Tokyo; hereinafter "Otsuka Pharmaceutical") has obtained manufacturing and marketing approval in Japan for Hemsite®, a gene panel test for hematologic malignancies. Hemsite® was co-designed by Otsuka Pharmaceutical and the National Cancer Center Japan (Location: Tokyo; hereinafter "NCCJ") and developed by a joint research consortium with the NCCJ, Kyushu University (Location: Fukuoka Prefecture), Kyoto University (Location: Kyoto Prefecture), Nagoya Medical Center, National Hospital Organization (Location: Aichi Prefecture), the Advanced Clinical Research Center at The Institute of Medical Science, The University of Tokyo (Location: Tokyo), and Keio University School of Medicine (Location: Tokyo). Moving forward, we will proceed with procedures for insurance coverage and prepare for its launch.

Please see below for the full press release.

Press Release (PDF)